MDGL News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

MD

Mkt Cap

$10.39B

Volume

281.31K

Next Earnings

November 3rd

Loading chart

MD

MDGLMadrigal Pharmaceuticals, Inc. Common Stock

MDGL

Pay with—

Available Balance0.00

MD

Mkt Cap

$10.62B

Volume

281.31K

Next Earnings

November 3rd

Chart Financials Earnings News About Insider Filings

Can NVO's Semaglutide Push Create Growth Beyond Cardiometabolic Care?Novo Nordisk is expanding semaglutide into new indications like MASH and obesity-related conditions to diversify revenue beyond its core GLP-1 franchise. However, the company faces significant competitive pressure from Eli Lilly's broad incretin portfolio expansion and other competitors in the MASH market. Novo's stock has underperformed the industry year-to-date, trading at a discount valuation with a Hold rating.Zacks Investment Research · Oct 7, 2026

3 Under-the-Radar Stocks to Buy and Hold for a DecadeThe article highlights three biotech companies with strong growth potential over the next decade: Madrigal Pharmaceuticals, which has the first-approved MASH treatment with significant market opportunity; Axsome Therapeutics, which is expanding its depression medicine Auvelity into Alzheimer's disease treatment; and Kailera Therapeutics, a newly public company developing weight-loss medicines in a fast-growing market. All three operate in high-need therapeutic areas with promising pipelines.The Motley Fool · Jun 16, 2026

Madrigal Pharmaceuticals to Release First-Quarter 2026 Financial Results and Host Webcast on May 6, 2026Madrigal Pharmaceuticals announced it will release Q1 2026 financial results on May 6, 2026, followed by a live webcast at 8 a.m. ET. The company is a biopharmaceutical firm focused on MASH treatment, with its FDA and European Commission-approved medication Rezdiffra (resmetirom) for moderate to advanced fibrosis cases, and an ongoing Phase 3 trial for cirrhosis treatment.GlobeNewswire Inc. · Apr 22, 2026

The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First StepThe regenerative medicine market, projected to reach $578 billion by 2033, faces a critical manufacturing challenge in scaling cell and gene therapies. Several companies are addressing this bottleneck through different approaches: Prime Medicine with prime editing technology, Madrigal Pharmaceuticals with sustained therapeutic results, Iovance Biotherapeutics with FDA-approved TIL therapy, Denali Therapeutics with protein engineering, and Avaí Bio with a Master Cell Bank for encapsulated cell products that enable off-the-shelf manufacturing.Benzinga · Apr 1, 2026

Prediction: 2 Stocks That Will Be Worth More Than Summit Therapeutics 1 Year From NowSummit Therapeutics faces significant near-term risk as its FDA decision on ivonescimab is expected by November 14, 2026. The drug failed to demonstrate statistically significant overall survival improvement in non-Chinese patient populations, which the FDA requires for approval. Meanwhile, Axsome Therapeutics and Madrigal Pharmaceuticals are positioned to potentially outperform Summit by year-end, driven by upcoming catalysts and strong revenue growth.The Motley Fool · Mar 25, 2026

This New $193 Million Bet Targets a Biotech With $689 Million in Revenue and a Potential Turnaround StoryRTW Investments established a new $193 million position in Apellis Pharmaceuticals by acquiring 7.67 million shares in Q4 2025. Despite a 29% stock decline over the past year, the investment signals confidence in the company's commercial-stage biotech portfolio, which generated $689 million in product revenue driven by its flagship therapy. The position represents a calculated pivot toward more durable revenue streams within a portfolio focused on high-growth biotech names.The Motley Fool · Mar 21, 2026

Madrigal Expands its MASH Pipeline with Exclusive Global Licensing Agreement for Six Preclinical siRNA ProgramsMadrigal Pharmaceuticals announced an exclusive global licensing agreement with Suzhou Ribo Life Science for six preclinical siRNA programs to expand its MASH treatment pipeline. The deal includes a $60 million upfront payment with potential cumulative payments reaching $4.4 billion upon milestone achievement. Madrigal's pipeline now includes over 10 programs anchored by its approved drug Rezdiffra, with additional candidates including MGL-2086 (GLP-1 agonist) and Ervogastat (DGAT-2 inhibitor) in development.GlobeNewswire Inc. · Feb 11, 2026

Roblox, First Solar, And League Enterprise Are Among Top 10 Large Cap Losers Last Week (Jan. 5-Jan. 9): Are the Others in Your Portfolio?Ten large-cap stocks experienced significant declines during the week of January 5-9, 2026. Notable losers include Madrigal Pharmaceuticals (down 11.57%), First Solar (down 14.46% following a Jefferies downgrade), Astera Labs (down 12.18%), and Roblox (down 9.99%). Other major decliners include CoStar Group, American International Group, NRG Energy, Las Vegas Sands, Johnson Controls International, and HDFC Bank. The declines were driven by analyst downgrades, leadership transitions, and executive changes.Benzinga · Jan 11, 2026

Madrigal Expands its MASH Pipeline with Exclusive Global License Agreement for Ervogastat, a Phase 2 Oral DGAT-2 InhibitorMadrigal Pharmaceuticals announced an exclusive global license agreement with Pfizer to develop ervogastat, a Phase 2 oral DGAT-2 inhibitor for MASH treatment. The deal includes a $50 million upfront payment to Pfizer, with ervogastat positioned as a complementary therapy to Madrigal's approved drug Rezdiffra for potential combination treatment. Madrigal plans to conduct drug-to-drug interaction studies and consult with the FDA on Phase 2 combination trial design in 2026.GlobeNewswire Inc. · Jan 9, 2026

Gene Therapy: 5 Biotech Stocks Chasing the $36B PrizeThe gene therapy market is projected to reach $36.55 billion by 2032, with the FDA approving three transformative cell therapies in December. Five biotech companies are advancing therapies across diabetes, sickle cell disease, cardiovascular disease, liver disease, and chronic granulomatous disease, with recent clinical data demonstrating significant efficacy and safety profiles.Benzinga · Jan 2, 2026

to start trading

MD

MDGLMadrigal Pharmaceuticals, Inc. Common Stock

MDGL

Pay with—

Available Balance0.00

Your PositionYou don't own any MDGL yet.

Related Tickers

Earnings